Hypophosphorylation of Mdm2 Augments p53 Stability

REFERENCES

• Argentini, M., N. Barboule, and B. Wasylyk. 2001. The contribution of the acidic domain of MDM2 to p53 and MDM2 stability. Oncogene 20: 1267–1275.
   PubMed Web of Science ®Google Scholar
• Attardi, L. D., and T. Jacks. 1999. The role of p53 in tumor suppression: lessons from mouse models. Cell. Mol. Life Sci. 55: 48–63.
   PubMed Web of Science ®Google Scholar
• Barak, Y., E. Gottlieb, G. T. Juven, and M. Oren. 1994. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with non-identical translation potential. Genes Dev. 8: 1739–1749.
   PubMed Web of Science ®Google Scholar
• Blattner, C., A. Sparks, and D. P. Lane. 1999. Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53. Mol. Cell. Biol. 19: 3704–3713.
   PubMed Web of Science ®Google Scholar
• Bottger, A., V. Bottger, A. Sparks, W.-L. Liu, S. F. Howard, and D. P. Lane. 1997. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol. 7: 860–869.
   PubMed Web of Science ®Google Scholar
• Cahilly-Snyder, L., T. Yang-Feng, U. Francke, and D. L. George. 1987. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat. Cell Mol. Genet. 13: 235–244.
   PubMedGoogle Scholar
• Chen, C., and H. Okayama. 1987. High efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol. 7: 2745–2752.
   PubMed Web of Science ®Google Scholar
• Chen, J., V. Marechal, and A. J. Levine. 1993. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 13: 4107–4114.
   PubMed Web of Science ®Google Scholar
• Ciechanover, A., H. Gonen, B. Bercovich, S. Cohen, I. Fajerman, A. Israel, F. Mercurio, C. Kahana, A. L. Schwartz, K. Iwai, and A. Orian. 2001. Mechanisms of ubiquitin-mediated, limited processing of the NF-kappaB1 precursor protein p105. Biochimie 83: 341–349.
   PubMedGoogle Scholar
• Ciechanover, A., A. Orian, and A. L. Schwartz. 2000. The ubiquitin mediated proteolytic pathway: mode of action and clinical implications. J. Cell. Biochem. Suppl. 34: 40–51.
   PubMedGoogle Scholar
• Evans, S. C., and G. Lozano. 1997. The Li-Fraumeni syndrome: an inherited susceptibility to cancer. Mol. Med. Today 3: 390–395.
   PubMedGoogle Scholar
• Grossman, S. R., M. Perez, A. L. Kung, M. Joseph, C. Mansur, Z. X. Xiao, S. Kumar, P. M. Howley, and D. M. Livingston. 1998. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol. Cell 4: 405–415.
   Google Scholar
• Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387: 296–299.
   PubMed Web of Science ®Google Scholar
• Hay, T. J., and D. W. Meek. 2000. Multiple sites of in vivo phosphorylation in the MDM2 oncoprotein cluster within two important functional domains. FEBS Lett. 478: 183–186.
   PubMed Web of Science ®Google Scholar
• Hengstermann, A., N. J. Whitaker, D. Zimmer, H. Zentgraf, and M. Scheffner. 1998. Characterization of sequence elements involved in p53 stability regulation reveals cell type dependence for p53 degradation. Oncogene 17: 2933–2941.
   PubMedGoogle Scholar
• Hjerrild, M., D. Milne, N. Dumaz, T. Hay, O. G. Issinger, and D. Meek. 2001. Phosphorylation of murine double minute clone 2 (MDM2) protein at serine-267 by protein kinase CK2 in vitro and in cultured cells. Biochem. J. 355: 347–356.
   PubMedGoogle Scholar
• Honda, R., and H. Yasuda. 1999. Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J. 18: 22–27.
   PubMed Web of Science ®Google Scholar
• Honda, R., H. Tanaka, and H. Yasuda. 1997. Oncoprotein Mdm2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420: 25–27.
   PubMed Web of Science ®Google Scholar
• Hsieh, J.-K., F. Chan, D. J. O'Connor, S. Mittnacht, S. Zhong, and X. Lu. 1999. RB regulates the stability and the apoptotic function of p53 via Mdm2. Mol. Cell 3: 1–20.
   PubMedGoogle Scholar
• Khosravi, R., R. Maya, T. Gottlieb, M. Oren, Y. Shiloh, and D. Shkedy. 1999. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc. Natl. Acad. Sci. USA 96: 14973–14977.
   PubMed Web of Science ®Google Scholar
• Kubbutat, M. H., S. N. Jones, and K. H. Vousden. 1997. Regulation of p53 stability by Mdm2. Nature 387: 299–303.
   PubMed Web of Science ®Google Scholar
• Leng, P., D. R. Brown, C. V. Shivakumar, S. Deb, and S. P. Deb. 1995. N-terminal 130 amino acids of MDM2 are sufficient to inhibit p53-mediated transcriptional activation. Oncogene 10: 1275–1282.
   PubMed Web of Science ®Google Scholar
• Maki, C. G., and P. M. Howley. 1997. Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol. Cell. Biol. 17: 355–363.
   PubMed Web of Science ®Google Scholar
• May, P., and E. May. 1999. Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene 18: 7621–7636.
   PubMed Web of Science ®Google Scholar
• Maya, R., M. Balass, S. T. Kim, D. Shkedy, J. F. Leal, O. Shifman, M. Moas, T. Buschmann, Z. Ronai, Y. Shiloh, M. B. Kastan, E. Katzir, and M. Oren. 2001. ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev. 15: 1067–1077.
   PubMed Web of Science ®Google Scholar
• Meek, D. W., and D. M. Milne. 2000. Analysis of multi-site phosphorylation of the p53 tumor-suppressor protein by tryptic phosphopeptide mapping. Methods Mol. Biol. 99: 447–463.
   PubMedGoogle Scholar
• Midgley, C. A., J. M. Desterro, M. K. Saville, S. Howard, A. Sparks, R. T. Hay, and D. P. Lane. 2000. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene 19: 2312–2323.
   PubMed Web of Science ®Google Scholar
• Midgley, C. A., C. J. Fisher, J. Bartek, B. Vojtesek, D. P. Lane, and D. M. Barnes. 1992. Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. J. Cell Sci. 101: 183–189.
   PubMed Web of Science ®Google Scholar
• Momand, J., H. H. Wu, and G. Dasgupta. 2000. MDM2—master regulator of the p53 tumor suppressor protein. Gene 242: 15–29.
   PubMed Web of Science ®Google Scholar
• Momand, J., G. P. Zambetti, D. C. Olson, D. George, and A. J. Levine. 1992. The mdm2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 92: 1237–1245.
   Google Scholar
• Oliner, J. D., J. A. Pietenpol, S. Thiagalingam, J. Gyuris, K. W. Kinzler, and B. Vogelstein. 1993. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362: 857–860.
   PubMed Web of Science ®Google Scholar
• Oren, M. 1999. Regulation of the p53 tumor suppressor protein. J. Biol. Chem. 274: 36031–36034.
   PubMed Web of Science ®Google Scholar
• Pommerantz, J., N. Schreiber-Agus, N. J. Liegeois, A. Silverman, L. Alland, L. Chin, J. Potes, K. Chen, I. Orlow, H.-W. Lee, C. Cordon-Cardo, and R. A. DePinho. 1998. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713–723.
   PubMedGoogle Scholar
• Rodriguez, M. S., J. M. Desterro, S. Lain, D. P. Lane, and R. T. Hay. 2000. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol. Cell. Biol. 20: 8458–8467.
   PubMed Web of Science ®Google Scholar
• Sionov, R. V., and Y. Haupt. 1999. The cellular response to p53: the decision between life and death. Oncogene 18: 6145–6157.
   PubMed Web of Science ®Google Scholar
• Stott, F. J., S. Bates, M. C. James, B. B. McConnell, M. Starborg, S. Brookes, I. Palmero, K. Ryan, E. Hara, K. H. Vousden, and G. Peters. 1998. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17: 5001–5014.
   PubMed Web of Science ®Google Scholar
• Takahashi, T., M. M. Nau, I. Chiba, M. J. Birrer, R. K. Rosenberg, M. Vinocour, M. Levitt, H. Pass, A. F. Gazdar, and J. D. Minna. 1989. p53: a frequent target for genetic abnormalities in lung cancer. Science 246: 491–494.
   PubMed Web of Science ®Google Scholar
• Treier, M., L. M. Staszewski, and D. Bohmann. 1994. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the δ-Domain. Cell 78: 787–798.
   PubMed Web of Science ®Google Scholar
• Van der Geer, P., and T. Hunter. 1994. Phosphopeptide mapping and phosphoamino acid analysis by electrophoresis and chromatography on thin-layer cellulose plates. Electrophoresis 15: 544–554.
   PubMed Web of Science ®Google Scholar
• Vojtesek, B., H. Dolezalova, L. Lauerova, M. Svitakova, P. Havlis, J. Kovarik, C. A. Midgley, and D. P. Lane. 1995. Conformational changes in p53 analyzed using new antibodies to the core DNA binding domain of the protein. Oncogene 10: 389–393.
   PubMed Web of Science ®Google Scholar
• Waseem, N. H., and D. P. Lane. 1990. Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA)—structural conservation and the detection of a nucleolar form. J. Cell Sci. 96: 121–129.
   PubMed Web of Science ®Google Scholar
• Weber, J. D., L. J. Taylor, M. F. Roussel, C. J. Sherr, and D. Bar-Sagi. 1999. Nucleolar Arf sequesters Mdm2 and activates p53. Nat. Cell. Biol. 1: 20–26.
   PubMed Web of Science ®Google Scholar